medical guideline
首页
中医/中西医结合指南
肿瘤学指南
泌尿外科指南
关于我们
郑重声明
联系我们
首页
肿瘤学指南
检索结果
人体系统
运动
骨肿瘤
软组织肿瘤
骨与软组织肿瘤
硬纤维瘤
骶尾部畸胎瘤
神经
中枢神经系统肿瘤
嗜铬细胞瘤和副神经节瘤
副神经节瘤
胶质细胞瘤
前庭神经鞘瘤
星形胶质细胞瘤和少突胶质细胞瘤
弥漫性胶质瘤
神经纤维瘤
神经细胞瘤
神经内分泌肿瘤
内分泌
甲状腺肿瘤
垂体肿瘤
肾上腺肿瘤
甲状旁腺肿瘤
胸腺肿瘤
神经内分泌肿瘤
循环
心脏肿瘤
淋巴瘤
骨髓瘤
白血病
血液肿瘤
血管瘤
呼吸
肺癌
鼻咽癌
喉部肿瘤
下咽癌
鼻腔和副鼻窦癌
呼吸道肿瘤
鼻颅咽管瘤
淋巴管肌瘤
消化
胰腺肿瘤
口腔癌
肛门癌
口咽癌
胆囊癌
胆管肿瘤
直肠癌
结肠癌
胃癌
小肠癌
肝癌
大肠肿瘤
唾液腺癌
阑尾肿瘤
食管肿瘤
肝肿瘤
壶腹肿瘤
肝胆癌
结直肠肿瘤
食管胃肿瘤
胃肠道肿瘤
消化道肿瘤
泌尿
膀胱肿瘤
肾癌
脐尿管癌
尿路上皮癌
肾血管平滑肌脂肪瘤
泌尿生殖肿瘤
生殖
女性
子宫肿瘤
卵巢肿瘤
乳腺肿瘤
阴道肿瘤
输卵管癌
外阴癌
妊娠滋养细胞肿瘤
妇科肿瘤
男性
前列腺肿瘤
性索间质瘤
睾丸肿瘤
阴茎癌
男性乳腺肿瘤
泌尿生殖肿瘤
其他
症状管理
治疗方案
诊断/检测/评估方法
预防和筛查
COVID-19大流行癌症患者相关指导建议
皮肤肿瘤
黑色素瘤
头颈部肿瘤
康复营养
生育能力
体力活动
心理健康
腹膜肿瘤
实体瘤
胸部肿瘤
长期监测
Cowden综合征
转诊
遗传性癌症综合征
癌症患者其他类问题管理
寡转移性疾病
基因测序
易感基因变异的分类
外科肿瘤
罕见癌症
不明原因癌症
纤维瘤
腹部肿瘤
老年肿瘤
儿童/青少年肿瘤
人类微生物组与癌变
检索结果
按关键字
按标题
按关键词
按摘要
按作者
按期刊
按发表年份
共搜索到
57条
与
adjuvant
有关的结果
Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline
2019年 发布于
American Society of Clinical Oncology
卷 第期
所属人体系统:
生殖
|
乳腺肿瘤
American Society of Clinical Oncology
Breast Cancer
Adjuvant Systemic Therapy
Early-Stage
指南简介
原文链接
Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline
2019年 发布于
American Society of Clinical Oncology
卷 第期
所属人体系统:
消化
|
胆管肿瘤
American Society of Clinical Oncology
Adjuvant Therapy
Biliary Tract Cancer
Resected
指南简介
原文链接
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women with Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline—Integration of Results from TAILORx
2019年 发布于
American Society of Clinical Oncology
卷 第期
所属人体系统:
生殖
|
乳腺肿瘤
American Society of Clinical Oncology
Breast Cancer
Early-Stage
Adjuvant Systemic Therapy
Biomarkers
指南简介
原文链接
Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline
2019年 发布于
Journal of Clinical Oncology
37卷 第12期
所属人体系统:
消化
|
胆管肿瘤
American Society of Clinical Oncology
Biliary Tract Cancer
Adjuvant Therapy
Guideline
指南简介
原文链接
Controversies, Consensus, and Collaboration in the Use of I-131 Therapy in Differentiated Thyroid Cancer: a Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular
2019年 发布于
Thyroid
29卷 第4期
所属人体系统:
内分泌
|
甲状腺肿瘤
American Thyroid Association
the European Association of Nuclear Medicine
the Society of Nuclear Medicine and Molecular Imaging
and the European Thyroid Association
Adjuvant Therapy
Consensus
Differentiated Thyroid Cancer
Radioiodine-refractory Thyroid Cancer
Remnant Ablation.
指南简介
原文链接
Controversies, Consensus, and Collaboration in the Use of 131I Therapy in Differentiated Thyroid Cancer: a Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular I
2019年 发布于
Thyroid
29卷 第4期
所属人体系统:
内分泌
|
甲状腺肿瘤
American Thyroid Association
the European Association of Nuclear Medicine
the Society of Nuclear Medicine and Molecular I
Adjuvant Therapy
Consensus
Differentiated Thyroid Cancer
Radioiodine-refractory Thyroid Cancer
Remnant Ablation
指南简介
原文链接
Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline
2019年 发布于
J Clin Oncol
37卷 第16期
所属人体系统:
消化
|
结肠癌
American Society of Clinical Oncology
Stage III Colon Cancer
Adjuvant Therapy
Oxaliplatin
Guideline
指南简介
原文链接
SIU-ICUD Consultation on Bladder Cancer: Treatment of Muscle-invasive Bladder Cancer
2019年 发布于
World J Urol
37卷 第1期
所属人体系统:
泌尿
|
膀胱肿瘤
无
Adjuvant Chemotherapy
Bladder-sparing
Chemoradiation
Enhanced Recovery after Surgery
Muscle-invasive Bladder Cancer
Neo
adjuvant
Chemotherapy
Radical Cystectomy
Transurethral Resection of Bladder Tumor
Trimodal
Urothelial Carcinoma of Bladder
Variant Histology
指南简介
原文链接
GEFPICS’ Guidelines for Management of Breast Cancer Tissue Samples in the Neoadjuvant Setting
2019年 发布于
Ann Pathol
39卷 第6期
所属人体系统:
生殖
|
乳腺肿瘤
Groupe D’étude Des Facteurs Pronostiques Immunohistochimiques Dans Le Cancer Du Sein
Unicancer
Breast Cancer
Cancer Du Sein
Guidelines
Neo
adjuvant
Néo
adjuvant
Pathological Response
Prélèvement
Recommandations
Réponse Pathologique
Tissue Sample
指南简介
原文链接
SEOM Clinical Guidelines in Early Stage Breast Cancer (2018)
2019年 发布于
Clin Transl Oncol
21卷 第1期
所属人体系统:
生殖
|
乳腺肿瘤
Spanish Society of Medical Oncology
Adjuvant
Early Breast Cancer
Follow-up
Genomic Predictive Test
Neo
adjuvant
指南简介
原文链接
Estimating the Benefits of Therapy for Early-stage Breast Cancer: the St. Gallen International Consensus Guidelines for the Primary Therapy of Early Breast Cancer 2019
2019年 发布于
Ann Oncol .
30卷 第10期
所属人体系统:
生殖
|
乳腺肿瘤
无
St. Gallen Consensus
Early Breast Cancer
Radiation Therapy
Surgery
Systemic Adjuvant Therapies
指南简介
原文链接
Diagnostic Value of Imaging (ultrasonography, Doppler, CT, MR, PET-CT) for the Diagnosis of a Suspicious Ovarian Mass and Staging of Ovarian, Tubal Or Primary Peritoneal Cancer: Article Drafted from the French Guidelines in Oncology Entitled `Initial Man
2019年 发布于
Gynecol Obstet Fertil Senol
47卷 第2期
所属人体系统:
其他
|
腹膜肿瘤
FRANCOGYN (Groupe Français De Recherche En Chirurgie Oncologique Et Gynécologique)
Au CNGOF (Collège National Des Gynécologues Obstétriciens Français)
À La SFOG (Société Française D’oncologie Gynécologique Et Au Groupe GINECO-ARCAGY (Groupe D’investigateurs Nationaux Pour L’étude Des Cancers Ovariens Et Du Sein – Association De Recherche Sur Les Cancers Dont Gynécologiques) Et Sont Labellisées Par L’INCa (Institut National Du Cancer).
Transvaginal Ultrasound Is the First-line Examination Allowing Characterizing 80 to 90% of Adnexal Masses (LP1). If Performed by an Expert
a Subjective Analysis Is Optimal. If Performed by a Non-expert
Combining the Use of Simple Rules with Subjective Analysis Can Achieve the Diagnostic Performance of an Expert (LP1). Whichever the Chosen Model (subjective Analysis by an Expert Or Combination of the Simple Rules with a Subjective Analysis by a Non-expert)
a Second-line Examination Will Have to Be Proposed in the Complex Or Indeterminate Cases (about 20% of the Masses) (grade A). the Best-performing Second-line Test for Characterization Is Pelvic MRI (LP1). If Read by an Expert
a Pathological Hypothesis Can Or Should Be Suggested (grade D). in Case of Non-expert Reading
the Use of the ADNEXMR Score Allows a Reliable Assessment of the Positive Predictive Value of Malignancy to Guide the Patient Towards the Best Management (gradeC). for Preoperative Assessment and Evaluation of Resectability of Ovarian
Fallopian Tube Or Primary Peritoneal Cancer
It Is Recommended to Perform a Chest Abdomen and Pelvis CT with Contrast Agent Injection (LP2
Grade B). in the Event of a Contraindication to the Injection of Iodinated Contrast Agent (severe Renal Insufficiency
GFR <30mL/min)
an Abdomen and Pelvis MRI Completed with a Non-injected Chest CT May Be Proposed (LP3
Grade C). by Analogy
the Same Examinations Are Recommended to Evaluate the Disease after Neo-
adjuvant
Chemotherapy (LP3
Recommendation Grade C). Further Studies Will Be Required to Determine Whether PET-CT Provides Better Lymph Node Assessment Before Retroperitoneal and Pelvic Lymphadenectomy. PET-CT May Be Used to Eliminate Lymph Node Involvement in the Absence of Suspicious Lymph Nodes on Morphological Examination (LP3
Grade C). the Report Should Specify the Localizations Leading to a Risk of Incomplete Cytoreductive Surgery and Lesions Outside the Field Explored During Surgery.
指南简介
原文链接
Management of Epithelial Cancer of the Ovary, Fallopian Tube, and Primary Peritoneum. Short Text of the French Clinical Practice Guidelines Issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARCAGY, and Endorsed by INCa
2019年 发布于
Eur J Obstet Gynecol Reprod Biol
236卷 第_期
所属人体系统:
其他
|
腹膜肿瘤
FRANçais De Recherche En Chirurgie Oncologique Et GYNécologique (FRANCOGYN)
Le Collège National Des Gynécologues Et Obstétriciens Français (CNGOF)
La Société Française D’oncologie Gynécologique (SFOG) Et Le Groupe D’investigateurs National Des Études Des Cancers Ovariens Et Du Sein (GINECO-ARCAGY) Et De L’institut National Du Cancer (INCa)
An MRI Is Recommended for an Ovarian Mass That Is Indeterminate on Ultrasound. the ROMA Score (combining CA125 and HE4) Can Also Be Calculated (Grade A). in Presumed Early-stage Ovarian Or Tubal Cancers
the Following Procedures Should Be Performed: an Omentectomy (at a Minimum
Infracolic)
an Appendectomy
Multiple Peritoneal Biopsies
Peritoneal Cytology (grade C)
and Pelvic and Para-aortic Lymphadenectomies (Grade B) for All Histologic Types
Except the Expansile Mucinous Subtypes
for Which Lymphadenectomies Can Be Omitted (grade C). Minimally Invasive Surgery Is Recommended for Early-stage Ovarian Cancer
When There Is No Risk of Tumor Rupture (grade B). Adjuvant Chemotherapy by Carboplatin and Paclitaxel Is Recommended for All High-grade Ovarian and Tubal Cancers (FIGO Stages I-IIA) (grade A). for FIGO Stage III Or IV Ovarian
Tubal
and Primary Peritoneal Cancers
a Contrast-enhanced Computed Tomography (CT) Scan of the Thorax/abdomen/pelvis Is Recommended (Grade B)
as Well as Laparoscopic Exploration to Take Multiple Biopsies (grade A) and a Carcinomatosis Score (Fagotti Score at a Minimum) (grade C) to Assess the Possibility of Complete Surgery (i.e.
Leaving No Macroscopic Tumor Residue). Complete Surgery by a Midline Laparotomy Is Recommended for Advanced Ovarian
Tubal
Or Primary Peritoneal Cancers (grade B). for Advanced Cancers
Para-aortic and Pelvic Lymphadenectomies Are Recommended When Metastatic Adenopathy Is Clinically Or Radiologically Suspected (grade B). When Adenopathy Is Not Suspected and When Complete Peritoneal Surgery Is Performed as the Initial Surgery for Advanced Cancer
the Lymphadenectomies Can Be Omitted Because They Do Not Modify Either the Medical Treatment Or Overall Survival (grade B). Primary Surgery (before Other Treatment) Is Recommended Whenever It Appears Possible to Leave No Tumor Residue (grade B). after Primary Surgery Is Complete
6 Cycles of Intravenous Chemotherapy (grade A) Are Recommended
Or a Discussion with the Patient About Intraperitoneal Chemotherapy
According to Her Risk-benefit Ratio. after Complete Interval Surgery for FIGO Stage III Disease
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Can Be Proposed
in Accordance with the Modalities of the OV-HIPEC Trial (grade B). in Cases of Postoperative Tumor Residue Or in FIGO Stage IV Tumors
Chemotherapy Associated with Bevacizumab Is Recommended (grade A).
指南简介
原文链接
Expert Panel Consensus on Pathological Diagnosis of Breast Cancer with Neoadjuvant Therapy, the 2020 Version
2020年 发布于
Zhonghua Bing Li Xue Za Zhi
49卷 第4期
所属人体系统:
生殖
|
乳腺肿瘤
Members of Breast Cancer Expert Panel on Consensus 2020
Breast Cancer
Pathological Diagnosis
Neo
adjuvant
Therapy
Consensus
指南简介
原文链接
Expert Consensus on Neoadjuvant Immunotherapy for Non-small Cell Lung Cancer
2020年 发布于
Transl Lung Cancer Res
9卷 第6期
所属人体系统:
呼吸
|
肺癌
无
Non-small Cell Lung Cancer
Neo
adjuvant
Immunotherapy
Consensus
指南简介
原文链接
Therapy for Stage IV Non–Small-Cell Lung Cancer without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update
2020年 发布于
American Society of Clinical Oncology
卷 第期
所属人体系统:
呼吸
|
肺癌
American Society of Clinical Oncology
Non-Small Cell Lung Cancer
Stage IV
Therapy
Driver Alterations
Chemotherapy
Adjuvant
Immunosuppressive Agents
指南简介
原文链接
Guideline for Limb-Salvage Treatment of Osteosarcoma
2020年 发布于
Orthop Surg
12卷 第4期
所属人体系统:
运动
|
骨肿瘤
Bone Oncology Group of the Chinese Orthopaedic Association
Limb-salvage Therapy
Neo
adjuvant
Chemotherapy
Osteosarcoma
指南简介
原文链接
Systemic Adjuvant Therapy for Adult Patients at High Risk for Recurrent Cutaneous Or Mucosal Melanoma: an Ontario Health (cancer Care Ontario) Clinical Practice Guideline
2020年 发布于
Current Oncology
27卷 第1期
所属人体系统:
其他
|
黑色素瘤
Evidence-Based Care (pebc) at Ontario Health (Cancer Care Ontario)
Melanoma Disease Site Group
Melanoma
Adjuvant Therapy
Immune Checkpoint Inhibitors
Interferon
Practice Guidelines
Targeted Therapy.
指南简介
原文链接
ESMO Consensus Conference Recommendations on the Management of Locoregional Melanoma: Under the Auspices of the ESMO Guidelines Committee
2020年 发布于
Ann Oncol
31卷 第11期
所属人体系统:
其他
|
黑色素瘤
European Society for Medical Oncology
Adjuvant
Consensus
Immunotherapy
Melanoma
Targeted Therapy
Treatment.
指南简介
原文链接
European Consensus-based Interdisciplinary Guideline for Melanoma. Part 2: Treatment - Update 2019.
2020年 发布于
Eur J Cancer
126卷 第期
所属人体系统:
其他
|
黑色素瘤
European Dermatology Forum
European Association of Dermato-Oncology
European Organization of Research and Treatment of Cancer
Adjuvant Treatment
Cutaneous Melanoma
Excisional Margins
Interferon-α
指南简介
原文链接
首页
上一页
1
2
3
下一页
尾页
共57条,每页显示
20条
50条
100条
跳转至第
页
确定